The aim of this study was to evaluate tumor necrosis factor receptor superfamily member 17 (TNFRSF17) as a plasma cell-specific marker in BLCA and test its utility, combined with PD-L1, for patient stratification receiving ICB therapy.<h4>Methods</h4>Transcriptomic and clinical data from publicly available cohorts were analyzed. This evidence concerns the gene CD274 and bladder transitional cell carcinoma.